LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Letter regarding the paper "Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus".

    Cordero, Alberto / Fernandez Olmo, Rosa

    European heart journal. Quality of care & clinical outcomes

    2023  Volume 9, Issue 5, Page(s) 546

    MeSH term(s) Humans ; Cholesterol ; Diabetes Mellitus, Type 2 ; Heart Failure/epidemiology ; Heart Failure/etiology
    Chemical Substances Cholesterol (97C5T2UQ7J)
    Language English
    Publishing date 2023-06-30
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2823451-0
    ISSN 2058-1742 ; 2058-5225
    ISSN (online) 2058-1742
    ISSN 2058-5225
    DOI 10.1093/ehjqcco/qcad039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Cardiovascular considerations on recreational scuba diving. SEC-Clinical Cardiology Association/SEC-Working Group on Sports Cardiology consensus document.

    Tello Montoliu, Antonio / Olea González, Agustín / Pujante Escudero, Ángel / Martínez Del Villar, María / de la Guía Galipienso, Fernando / Díaz González, Leonel / Fernández Olmo, Rosa / Freixa-Pamias, Román / Vivas Balcones, David

    Revista espanola de cardiologia (English ed.)

    2024  

    Abstract: The practice of recreational scuba diving has increased worldwide, with millions of people taking part each year. The aquatic environment is a hostile setting that requires human physiology to adapt by undergoing a series of changes that stress the body. ...

    Abstract The practice of recreational scuba diving has increased worldwide, with millions of people taking part each year. The aquatic environment is a hostile setting that requires human physiology to adapt by undergoing a series of changes that stress the body. Therefore, physical fitness and control of cardiovascular risk factors are essential for practicing this sport. Medical assessment is not mandatory before participating in this sport and is only required when recommended by a health questionnaire designed for this purpose. However, due to the significance of cardiovascular disease, cardiology consultations are becoming more frequent. The aim of the present consensus document is to describe the cardiovascular physiological changes that occur during diving, focusing on related cardiovascular diseases, their management, and follow-up recommendations. The assessment and follow-up of individuals who practice diving with previous cardiovascular disease are also discussed. This document, endorsed by the Clinical Cardiology Association of the Spanish Society of Cardiology (SEC) and the SEC Working Group on Sports Cardiology of the Association of Preventive Cardiology, aims to assist both cardiologists in evaluating patients, as well as other specialists responsible for assessing individuals' fitness for diving practice.
    Language Spanish
    Publishing date 2024-04-03
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 2592481-3
    ISSN 1885-5857 ; 1885-5857
    ISSN (online) 1885-5857
    ISSN 1885-5857
    DOI 10.1016/j.rec.2024.04.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction.

    Miñana, Gema / Cordero, Alberto / Fácila, Lorenzo / Company, Mireia / Fernández-Cisnal, Agustín / Valero, Ernesto / Carratalá, Arturo / Navarro, Jorge / Llergo, Javier Torres / Fernández-Olmo, Rosa / Castro, Almudena / Bodi, Vicent / Sanchis, Juan / Núñez, Julio

    The American journal of cardiology

    2023  Volume 211, Page(s) 9–16

    Abstract: Lipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer, especially for predicting the risk of long- ... ...

    Abstract Lipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer, especially for predicting the risk of long-term recurrent AMI. We aimed to assess the relation between Lp(a) and very long-term recurrent AMI after an index episode of AMI. It is a retrospective analysis that included 1,223 consecutive patients with an AMI discharged from October 2000 to June 2003 in a single-teaching center. Lp(a) was assessed during index admission in all cases. The relation between Lp(a) at discharge and total recurrent AMI was evaluated through negative binomial regression. The mean age of the patients was 67.0 ± 12.3 years, 379 (31.0%) were women, and 394 (32.2%) were diabetic. The index event was more frequently non-ST-segment elevation myocardial infarction (66.0%). The median Lp(a) was 28.8 (11.8 to 63.4) mg/100 ml. During a median follow-up of 9.9 (4.6 to 15.5) years, 813 (66.6%) deaths and 1,205 AMI in 532 patients (43.5%) occurred. Lp(a) values were not associated with an increased risk of long-term all-cause mortality (p = 0.934). However, they were positively and nonlinearly associated with an increased risk of total long-term reinfarction (p = 0.016). In the subgroup analysis, there was no evidence of a differential effect for the most prevalent subgroups. In conclusion, after an AMI, elevated Lp(a) values assessed during hospitalization were associated with an increased risk of recurrent reinfarction in the very long term. Further prospective studies are warranted to evaluate their clinical implications.
    MeSH term(s) Humans ; Female ; Middle Aged ; Aged ; Male ; Retrospective Studies ; Lipoprotein(a) ; Myocardial Infarction/epidemiology ; Myocardial Ischemia ; Hospitalization ; Non-ST Elevated Myocardial Infarction ; Risk Factors
    Chemical Substances Lipoprotein(a)
    Language English
    Publishing date 2023-10-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/j.amjcard.2023.10.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.

    Cordero, Alberto / Fernandez Olmo, Rosa / Santos-Gallego, Carlos García / Fácila, Lorenzo / Bonanad, Clara / Castellano, José María / Rodriguez-Mañero, Moisés / Seijas-Amigo, José / González-Juanatey, José R / Badimon, Juan J

    The American journal of cardiology

    2023  Volume 205, Page(s) 321–324

    Abstract: Bempedoic acid is a selective inhibitor of the adenosine triphosphate citrate lyase that reduces low-density lipoprotein cholesterol (LDLc) levels by 17% to 28%. Although the Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, ...

    Abstract Bempedoic acid is a selective inhibitor of the adenosine triphosphate citrate lyase that reduces low-density lipoprotein cholesterol (LDLc) levels by 17% to 28%. Although the Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (CLEAR-OUTCOMES) trials demonstrated the efficacy on cardiovascular outcomes there is a controversy related to the possible net clinical benefit. Thereafter, we performed an intention-to-treat meta-analysis in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome of the metanalysis was the incidence of major adverse cardiovascular events, defined by each study protocol. Secondary outcomes for the analyses were myocardial infarction, stroke, myocardial revascularization, cardiovascular death, and all-cause death. Results of 4 clinical trials evaluated contained a total of 17,324 patients; 9,236 received bempedoic acid for a median of 46.6 months. The mean baseline LDLc was 129.4 (22.8) mg/100 ml and treatment was associated with a mean LDLc reduction of 26.0 (12.6) mg/100 ml. Treatment with bempedoic acid significantly reduced the incidence of major adverse cardiovascular events (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.81 to 0.96), myocardial infarction (HR 0.76, 95% CI 0.66 to 0.89) and myocardial revascularization (HR 0.82, 95% CI 0.73 to 0.92); the crude incidence of stroke, cardiovascular or all-cause mortality were lower in patients in the bempedoic acid groups although no significant risk reduction was observed. No heterogeneity was observed in any of the end points. In conclusion, the metanalysis of the 4 clinical trials currently available with bempedoic acid provides reliable evidence of its clinical benefit with no signs of heterogeneity or harm.
    MeSH term(s) Humans ; Randomized Controlled Trials as Topic ; Dicarboxylic Acids/therapeutic use ; Fatty Acids/therapeutic use ; Myocardial Infarction/drug therapy ; Myocardial Infarction/epidemiology ; Stroke
    Chemical Substances 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1EJ6Z6Q368) ; Dicarboxylic Acids ; Fatty Acids
    Language English
    Publishing date 2023-08-25
    Publishing country United States
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/j.amjcard.2023.07.145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.

    Cordero, Alberto / Fernández Olmo, Rosa / Badimon, Lina / Santos-Gallego, Carlos G / Castellano, José M / Fácila, Lorenzo / Rodriguez-Manero, Moisés / Bonanad, Clara / Vilahur, Gemma / Escribano, David / Badimon, Juan J / González-Juanatey, José R

    Journal of clinical lipidology

    2023  Volume 17, Issue 5, Page(s) 602–611

    Abstract: Background: Statins are the cornerstone of lipid-lowering therapy (LLT) for reduction of low-density lipoprotein cholesterol (LDLc) levels and high percentage of patients require LLT combinations or alternative treatments for adequate LDLc control.: ... ...

    Abstract Background: Statins are the cornerstone of lipid-lowering therapy (LLT) for reduction of low-density lipoprotein cholesterol (LDLc) levels and high percentage of patients require LLT combinations or alternative treatments for adequate LDLc control.
    Methods: We performed an intention-to-treat meta-analysis of published data of phase III trials evaluating LLT efficacy on major adverse cardiovascular events (MACE). The primary endpoint was MACE incidence, as reported in each trial, and secondary analyses included myocardial infarction, stroke and mortality.
    Results: Eleven clinical trials and 135,688 patients were included; seven trials tested high intensity LLT and 4 LLT combinations. Intensive LLT reduced MACE risk by 15% (12.03% vs. 13.79%, HR: 0.85 95% CI 0.80-0.90; p<0.001). The number needed to treat was 56 patients. Meta-regression analyses showed a linear correlation between absolute LDLc reductions and the risk of MACE. Significant reductions in myocardial infarction (HR: 0.83, 95% CI 0.80-0.86) and stroke (HR: 0.81, 95% CI 0.75-0.87) were observed. Cardiovascular death rate was 3.32% in LLT treatment arm vs. 3.56% in controls, resulting in a HR: 0.94 (95% CI 0.88-0.99; p = 0.03); no effect on all-cause mortality was observed (HR: 0.97 95% CI 0.93-1.01; p = 0.09). The sensitivity analyses verified the lack of heterogeneity, except for MACE that was mainly driven by the divergent results of the 2 trials. Small study effect was detected for the assessment of mortality.
    Conclusions: Current evidence consistently supports the efficacy of available intensity LLT for LDLc decrease on MACE and cardiovascular mortality reduction.
    MeSH term(s) Humans ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Myocardial Infarction ; Stroke/prevention & control ; Clinical Trials, Phase III as Topic
    Chemical Substances Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2023-08-22
    Publishing country United States
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 2365061-8
    ISSN 1876-4789 ; 1933-2874
    ISSN (online) 1876-4789
    ISSN 1933-2874
    DOI 10.1016/j.jacl.2023.08.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Cardiovascular prevention in elderly patients.

    Bonanad, Clara / Fernández-Olmo, Rosa / García-Blas, Sergio / Alarcon, Jose Antonio / Díez-Villanueva, Pablo / Mansilla, Carmen Rus / García-Pardo, Héctor / Toledo, Pablo / Ayesta, Ana / Pereira, Eva / Carol, Antoni / Castro-Conde, Almudena / de Pablo-Zarzoso, Carmen / Martínez-Sellés, Manuel / Arrarte, Vicente / Campuzano, Raquel / Ariza-Solé, Albert

    Journal of geriatric cardiology : JGC

    2022  Volume 19, Issue 5, Page(s) 377–392

    Abstract: In recent decades, life expectancy has been increasing significantly. In this scenario, health interventions are necessary to improve prognosis and quality of life of elderly with cardiovascular risk factors and cardiovascular disease. However, the ... ...

    Abstract In recent decades, life expectancy has been increasing significantly. In this scenario, health interventions are necessary to improve prognosis and quality of life of elderly with cardiovascular risk factors and cardiovascular disease. However, the number of elderly patients included in clinical trials is low, thus current clinical practice guidelines do not include specific recommendations. This document aims to review prevention recommendations focused in patients ≥ 75 years with high or very high cardiovascular risk, regarding objectives, medical treatment options and also including physical exercise and their inclusion in cardiac rehabilitation programs. Also, we will show why geriatric syndromes such as frailty, dependence, cognitive impairment, and nutritional status, as well as comorbidities, ought to be considered in this population regarding their important prognostic impact.
    Language English
    Publishing date 2022-06-11
    Publishing country China
    Document type Journal Article
    ZDB-ID 2421391-3
    ISSN 1671-5411
    ISSN 1671-5411
    DOI 10.11909/j.issn.1671-5411.2022.05.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis.

    Bonanad, Clara / García-Blas, Sergio / Torres Llergo, Javier / Fernández-Olmo, Rosa / Díez-Villanueva, Pablo / Ariza-Solé, Albert / Martínez-Sellés, Manuel / Raposeiras, Sergio / Ayesta, Ana / Bertomeu-González, Vicente / Tarazona Santabalbina, Francisco / Facila, Lorenzo / Vivas, David / Gabaldón-Pérez, Ana / Bodi, Vicente / Nuñez, Julio / Cordero, Alberto

    Journal of clinical medicine

    2021  Volume 10, Issue 22

    Abstract: Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF). This meta-analysis aims to assess the effect of DOACS vs. ...

    Abstract Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF). This meta-analysis aims to assess the effect of DOACS vs. VKA in patients ≥ 80 and AF. Primary endpoints were stroke or systemic embolism and all-cause death. Secondary endpoints included major bleeding, intracranial bleeding, and gastrointestinal bleeding. A random-effects model was selected due to significant heterogeneity. A total of 147,067 patients from 16 studies were included, 71,913 (48.90%) treated with DOACs and 75,154 with VKA (51.10%). The stroke rate was significantly lower in DOACs group compared with warfarin group (Relative risk (RR): 0.72; 95% confidence interval (CI): 0.63-0.82;
    Language English
    Publishing date 2021-11-12
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10225268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top